US Patent Issued to Grey Wolf Therapeutics on Oct. 27 for "Compounds as modulators of endoplasmic reticulum aminopeptidase 1 (ERAP1)" (British Inventors)

ALEXANDRIA, Va., Oct. 27 -- United States Patent no. 12,774,291, issued on Oct. 27, was assigned to Grey Wolf Therapeutics Ltd. (Abingdon, Great Britain).

"Compounds as modulators of endoplasmic reticulum aminopeptidase 1 (ERAP1)" was invented by Martin Quibell (Oxford, Great Britain), Jason John Shiers (Oxford, Great Britain), Michael Sparenberg (Oxford, Great Britain) and Eleanor Ivens (Oxford, Great Britain).

According to the abstract* released by the U.S. Patent & Trademark Office: "A compound of formula (I-1), or a pharmaceutically accept able salt or hydrate thereof, formula (I-1) wherein: ring A is a monocyclic 5, 6, or 7-membered heterocycloalkyl ring optionally substituted by one or more substituents selected from alkyl, CN, cycl...